Otros idiomas WntResearch AB

Acciones

WNT

SE0003553130

Precio de cierre NORDIC GROWTH MARKET Otros sitios de cotización 00:00:00 31/01/2024			Varia. Cinco días.	Varia. 1 de enero.
0,067 ^SEK	-.--%		-.--%	-27,17 %

03/05	WntResearch AB comunica los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
29/02	WntResearch AB comunica los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

WntResearch's CEO to BioStock: "If the effect is confirmed, there are good opportunities for licensing agreements next year"	08/05
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
BioStock: WntResearch's new CEO comments on his first month in the position	02/04
Resigning WntResearch CEO tells BioStock: "It will be exciting to follow!"	01/03
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea	26/02
WntResearch Initiates Collaboration with Business Sweden with the Goal of Establishing Commercial Partnerships for Foxy-5 in Japan and South Korea	26/02
WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5	12/02
WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5	12/02
WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8	08/02
WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	07/02
WntResearch publishes outcome in rights issue	31/01
WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024	24/01
WntResearch Announces CEO Changes	10/01
WntResearch publishes prospectus in connection with rights issue	08/01
Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023	22/12
WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5	06/12
WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5	06/12
WntResearch's CEO: "In a better position than ever"	21/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas WntResearch AB

Acciones

WNT

SE0003553130

Otros idiomas

Filtros